These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 8692981)

  • 1. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
    Nagy A; Schally AV; Armatis P; Szepeshazi K; Halmos G; Kovacs M; Zarandi M; Groot K; Miyazaki M; Jungwirth A; Horvath J
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7269-73. PubMed ID: 8692981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups.
    Janáky T; Juhász A; Bajusz S; Csernus V; Srkalovic G; Bokser L; Milovanovic S; Redding TW; Rékási Z; Nagy A
    Proc Natl Acad Sci U S A; 1992 Feb; 89(3):972-6. PubMed ID: 1310542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
    Nagy A; Schally AV; Halmos G; Armatis P; Cai RZ; Csernus V; Kovács M; Koppán M; Szepesházi K; Kahán Z
    Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1794-9. PubMed ID: 9465096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.
    Szepeshazi K; Schally AV; Nagy A; Halmos G; Groot K
    Anticancer Drugs; 1997 Nov; 8(10):974-87. PubMed ID: 9436641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties.
    Janáky T; Juhász A; Rékási Z; Serfözö P; Pinski J; Bokser L; Srkalovic G; Milovanovic S; Redding TW; Halmos G
    Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10203-7. PubMed ID: 1332035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6.
    Bajusz S; Janaky T; Csernus VJ; Bokser L; Fekete M; Srkalovic G; Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1989 Aug; 86(16):6318-22. PubMed ID: 2548207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
    Nagy A; Armatis P; Cai RZ; Szepeshazi K; Halmos G; Schally AV
    Proc Natl Acad Sci U S A; 1997 Jan; 94(2):652-6. PubMed ID: 9012839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone.
    Bajusz S; Janaky T; Csernus VJ; Bokser L; Fekete M; Srkalovic G; Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1989 Aug; 86(16):6313-7. PubMed ID: 2548206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
    Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
    Breast Cancer Res Treat; 2000 Feb; 59(3):255-62. PubMed ID: 10832595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers.
    Halmos G; Nagy A; Lamharzi N; Schally AV
    Cancer Lett; 1999 Mar; 136(2):129-36. PubMed ID: 10355741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
    Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.
    Kovacs M; Schally AV; Nagy A; Koppan M; Groot K
    Proc Natl Acad Sci U S A; 1997 Feb; 94(4):1420-5. PubMed ID: 9037068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
    Koppán M; Nagy A; Schally AV; Plonowski A; Halmos G; Arencibia JM; Groot K
    Prostate; 1999 Feb; 38(2):151-8. PubMed ID: 9973101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs.
    Szepeshazi K; Schally AV; Nagy A
    Breast Cancer Res Treat; 1999 Aug; 56(3):267-76. PubMed ID: 10573117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
    Nagy A; Schally AV
    Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.
    Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
    Cancer; 1999 Jun; 85(12):2608-15. PubMed ID: 10375109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on the function of rat pituitary cells: tests in a long term superfusion system.
    Rékási Z; Szöke B; Nagy A; Groot K; Rékási ES; Schally AV
    Endocrinology; 1993 May; 132(5):1991-2000. PubMed ID: 8477650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted cytotoxic analogue of luteinizing hormone-releasing hormone (LH-RH) only transiently decreases the gene expression of pituitary receptors for LH-RH.
    Kovacs M; Schally AV; Csernus B; Busto R; Rekasi Z; Nagy A
    J Neuroendocrinol; 2002 Jan; 14(1):5-13. PubMed ID: 11903807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.
    Nagy A; Plonowski A; Schally AV
    Proc Natl Acad Sci U S A; 2000 Jan; 97(2):829-34. PubMed ID: 10639165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
    Szepeshazi K; Schally AV; Halmos G
    Int J Oncol; 2007 Jun; 30(6):1485-92. PubMed ID: 17487370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.